Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

SOCRA SAMPLE QUESTIONS > Sample Test Questions > Flashcards

Sample Test Questions Flashcards

1
Q

The FDA requires specific elements to be included in an informed consent form? True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

For an industry sponsored trial, a site should allow only the sponsors monitor access to the regulatory files? True or false

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What FDA document must all investigators signed prior to participating in a drug clinical trial?

A

FDA 1572

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The purpose of an institutional review board is to assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights and welfare of human subjects. True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Only the principal investigator is allowed to transcribe data from the source document to the CRF. True or false

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

According to the FDA guidelines, the financial disclosure form should be completed by all study personnel that have second navigate role in the study. True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The contents of a protocol should generally contain:

  • Trial objectives and purpose
  • assessment of efficacy
  • Data handling and recordkeeping
  • all of the above
A

All of the above

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What date should an investigator write when he failed to sign the consent form on the date of consent?

A

Actual date of investigator signature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where would you look to find official government information regarding good clinical practice?

  • The investigators brochure
  • The US code of federal regulations
  • The protocol
  • All of the above
A

The US code of federal regulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

According to ICH guidelines, an IRB should have at least how many members?

A

5 members

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

According to you ICH guidelines, how long must an IRB retain its records for each research project?

A

3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When several hundred to several thousand subjects are in a study, what phase is the clinical investigation typically end?

A

Phase 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A statement regarding the confidentiality of the subject study records must be included in all informed consent documents? True or false

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

At a site initiation meeting the IRB should be invited to attend?

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The investigator should submit a summary of the trial status to the IRB at least:

  • Once a year
  • Every two years
  • Every three years
A

Once a year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

45CFR part 46 applies

A

To studies conducted or sponsored by the DHHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

The IRB is responsible for conducting its initial and continuing review and reporting its findings to

A

The investigator and the institution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

An essential element of informed consent affirmed the most ethical framework is

A

That participation be voluntary, without penalty or loss of benefits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

And essential element of consent that is affirmed in most ethical framework is that

A

Subject may discontinue participation at any time without penalty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The essential basic elements of consent include

A

A statement that the study involves research and its purpose, and description and identification of experimental procedures, the duration of the study, statements of the risk benefits and alternate procedures, any compensation for injury, and confidentiality of records and contact information regarding subject rights

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

An investigator is planning to submit a grant to a federal agency. Such applications

A

Need not be reviewed by the IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

An investigator for a study approved by a US IRB wishes to carry out the procedures related to a study in a foreign country. The situation requires

A

A translated consent form, disclosure to the US IRB, and an approval from the IRB in a foreign country

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which of the following is true regarding audit of the IRB?

  • OHRP does not carry out routine audits of the IRB
  • The FTA audits the IRB once every 3 to 5 years
  • The audit standards of the OHRP different from those of the FDA
  • All of the above
A

All of the above

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

FDA suspension of the IRB can entail

A

Withholding approval of new FDA studies, prevention of new subjects being added to existing clinical trials, termination of ongoing studies, and notification to other state and federal agencies of IRB noncompliance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

An electronic IRB

A

Must be part 11 compliant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

When an IRB takes on an external consultant for advice on a research study, the consultant

A

May not vote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

The Irb may charge sponsors for the study review

A

For a study review regardless of approval or disapproval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

A quality assurance program for clinical trials is

A

Is described by ICH- GCP but not by DHHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

The IRB registration is an application to the

A

DHHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Exam studies cannot be carried out with which study population

A

Prisoners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Exempt research is exempt from

A

DHHS regulations described in title 45 part 46

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

The IRB registration must be renewed every

A

3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

When the IRB makes a risk to benefit determination it should exclude

A

Procedures being performed for clinical treatment which are standard of care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Which of the following constitutes serious noncompliance in the IRB’s estimation?

A

Enrolling subjects without an authorized consent form, enrolling subjects during a lapse in IRB approval, making handwritten changes on the consent form for enrollment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

In assessing vulnerability of research subjects the IRB should

A

Whether the subjects may be subject to undue influence or coercion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

The primary responsibility of the IRB staff members is to

A

Prepare and maintain adequate documentation of IRB activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

According to NIH guidelines education on GCP and IRB issues is essential for

A

Key personnel conducting the research

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Gene therapy related studies must be reviewed by

A

IRB and IBC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

The FDA has deferred the initial decision regarding the non-significant risk for devices to

A

IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

The FDA has the authority to audit

A

The IRB, sponsors and clinical investigators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

IRB minutes should record

A

Number of members voting for, against and abstaining from the motion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

If a regular voting member and his ultimate net both attend the meeting then

A

Only the voting member can count toward the quorum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

According to DHHS regulations IRB records must include

A

Scientific valuations that accompany each proposal, reports for injuries to subjects, copies of all correspondence between the IRB and investigators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

The minutes of the IRB meeting should include sufficient detail to show attendance and practice this involves showing

A

The names of the attending’s and their representative roles, the earned degrees of the members attending, and the alternate members and who they are alternates for

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

During a meeting a voting member has a conflict of interest for a study being reviewed. The minutes must indicate

A

The name of the conflict a member, the name of the alternate who substitute it for the conflict a member if applicable, and the study for which the conflict was recorded.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

The IRB records must be maintained for how long after the completion of the

A

3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

An IRB member with a conflict of interest should

A

Not participate in the initial discussion or vote for the study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

IRB records must include

A

Research proposals reviewed, approved consent documents, continuing review activities and significant new findings provided to subjects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

When reviewing studies involving a vulnerable population in the IRB should

A

Ensure a protective measures relevant to the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

The DHHS regulations mention the following is a vulnerable category of subjects

A

Children, prisoners, pregnant women, and handicapped or mentally disabled persons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

The IRB should

A

Be sufficiently qualified through the experience and expertise of its members

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

When reviewing studies in specialized areas the IRB should

A

Invite competent consultants but not have them vote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

The IRB has a non-scientific member whose attendance at meetings is erratic and leads to loss of quorum the IRB may address the situation by

A

Appoint OHRP approved matching alternates for this number

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

With regard to a quorum add an IRB meeting the DHHS

A

Indicate only the majority of members including one scientific member must be present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

A quorum for an IRB meeting must contain

A

A non-scientific member

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

IRB reviewing an IND study of mass according to FDA guidelines have at least

A

One physician present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

An IRB has 15 members and 8 members are present, one of the members has a conflict of interest the IRB has to

A

vote at a future meeting where the appropriate number of members are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

And IRB meeting has six members and three members vote for the study in three vote to disapprove. The IRB

A

Must disapprove the study because majority is needed to approve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Exempt research

A

Is exempt from the regulations described in DHHS regulations and title 45 part 46

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Which population does not qualify for exempt research

A

Prisoners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Which of the following qualifies for exemption in children

A

Observation of public behavior in which the investigator does not participate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Taste in food quality studies

A

Would qualify for an exemption only if no harmful additives were involved, would qualify for an exemption if no supplements such as proteins or creatine are added, and is the only category comments above DHHSNFDA exemptions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Review of studies under the exempt category of collection of study of existing data is most frequently applicable to

A

Retrospective analysis of patient charts and medical records

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Survey and interview of public officials under the specific exempt category for these individuals

A

Is permissible using identifiers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Expedited review as applicable to

A

Research defined under the nine expedited categories in DHHS regulations, research that presents no more than minimal risk, minor changes to previously approved research.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Expedited review may be performed by

A

The IRB chair or his designee who is a member of the IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Investigator wishes to study the comparison of slow release hypertension drug to a rapid release hypertension drug with both drugs being used on label and not being under an IND. The study would

A

Qualify for expedited review

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

An investigator is collecting hair samples for a full genomics analysis to establish the ancestry of an isolated minority group. The study would

A

Need a review of convened IRB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

A survey of the views of subjects on climate change will be administered and identifiers will be collected. The study would qualify for

A

Expedited review

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

A phase 2 study has completed enrollment and all research activities are completed except follow up and data analysis which are ongoing. The study

A

Qualifies for an expedited continuing review

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

A waiver of informed consent is indicated if

A

The research involves no more than minimal risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Waiver of informed consent is indicated most frequently for which of the following situations

A

Research involving retrospective chart reviews

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Waiver of documentation of informed consent may be used for

A

Phone surveys of illegal behaviors, anonymous Internet-based surveys of sexual practices, and in person interviews of rape victims

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

A waiver of informed consent can be granted and a minimal rest study if the study cannot be practically carried out without the waiver. Impact ability may arise because

A

Large numbers of subjects are involved, records belong to a significant number of subjects who are lost to follow up, and direct contact with the subjects would be extremely difficult to establish.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Waiver of informed consent may be granted if

A

The research is no more than minimal risk, the rights and welfare of the subjects will not be affected, the research cannot be practically carried out without the waiver, and pertinent information will be provided after participation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

The regulations relating to research and prisoners and title 45 part 46 is described in

A

Part C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

With regard to payment of prisoners for research

A

The payment should be of such a magnitude that it does not distort the perception of risk in the limited environment of the prison

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Research and prisoners must ensure that

A

It is comparable and risk to that and non-prisoners, it must be immune from arbitrary intervention by prison authorities, pro boards will not take the prisoner participation into account and parole decisions, arrangements must be made for follow up care if applicable if the prisoner is released, control groups must be selected from among the available prisoners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Research and prisoners

A

Does not qualify for exempt review, should not be expedited according to the HOHRP guidance, and has specific categories which must be reviewed by 0HRP or the secretary of DHHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Any research involving more than minimal risk with prospect to benefit, the level of tolerable risk and research with children is defined as

A

The risk to benefit ratio should be at least as favorable as the alternative

81
Q

In a situation where assent of the child is required by the IRB but the investigator determines with medical advice from the child’s physician that the child is cognitively unable to ascend

A

The investigator may waive ascent

82
Q

Waiver of parental permission and research with children may be approved by the IRB if

A

Parental permission is not a reasonable requirement to protect the child, if neglect or abuse of child is involved, and if appropriate mechanisms to protect the child consistent with state law have a meet

83
Q

The most important consideration in reporting an adverse event in a clinical trial is

A

Whether the event occurred in the timeframe of drug administration

84
Q

A research subject enrolled in a clinical trial is involved in a car accident and suffered significant physical injuries. The event occurs while the drug administration phase of the protocol is still ongoing. The investigator should

A

Report the event to the sponsor and the IRB

85
Q

A research subject enrolled in a clinical trial experiences significant chest pain and is admitted to the emergency department for the possible evaluation of a cardiac event. The event occurs where are the drug administration is still ongoing in the clinical trial. The casualty of the event should be determined by

A

The principal investigator

86
Q

The sponsor must report a serious adverse event in an IND safety report to the FDA if the event is

A

Serious, unanticipated and possibly related to the drug

87
Q

In a clinical trial under an IND subject a experiences difficulty breathing and self admits to the emergency room. Subject b experiences nausea and vomiting which is resolved by home rest for a day. Which event should be reported as serious to the FDA?

A

Subject a

88
Q

For an adverse event to be characterized as unexpected OHRP guidance advises that the event should be in nature, severity or frequency be

A

Not listed in the research protocol, not listed in the informed consent, and not a characteristic of the study population.

89
Q

Adverse events encompss

A

Physical and physiological harms

90
Q

An adverse event is defined as serious as it is

A

Any of the following, death or life-threatening event, results in hospitalization or prolongation of hospitalization, results in a persistent or significant disability, or results in a congenital anomaly or birth defect

91
Q

In a clinical trial under an IND a death or life-threatening event should be reported to the FDA within

A

Seven days

92
Q

In a clinical trial under an IND an event that is serious but not a death or life-threatening event should be reported to the FDA within

A

15 days

93
Q

In a clinical trial serious adverse event should be reported by the investigator to the sponsor within

A

One day

94
Q

An investigator conducting a study of illicit drug behavior has the date on a laptop and an unencrypted fashion. The laptop is stolen. The event is

A

Unanticipated problem that does not involve an adverse event needs to be reported under DHHS regulations

95
Q

A pharmacist made a dosing error in a clinical trial that results in no harm to any subject. The event is

A

Unanticipate a problem that does not involve an adverse event needs to be reported under DHHS regulations

96
Q

A subject with a psychology study requires sequestration in a small space and develops claustrophobia which is described as one of the risks in the IRB approved protocol. The event is

A

Adverse event that does not represent an unanticipated problem and does not need to be reported

97
Q

A protocol deviation is

A

Any departure from the procedures and practices described in an IRB approved protocol, any action associated with regulatory noncompliance, or failure to follow the appropriate procedure or protocol for the informed consent process.

98
Q

A pharmacist providing an investigational drug for a phase 1 protocol makes an error in the dosing which is not associated with any adverse event in the subject. The event is

A

A protocol deviation, and an unanticipated event of risk to self or others

99
Q

One of the most common protocol deviations is

A

Missed or late study visit because of patient noncompliance

100
Q

During the study monitoring visit it was noted that a sample for laboratory analysis were being shipped long after the required shipment date. Many of the samples were deemed non-valuable. The event is

A

Protocol deviation

101
Q

Laboratory related protocol deviations can include

A

Improper lab sample collection, and proper shipment of lab sample which results in a non-valuable sample, improper storage of the sample prior to shipment, and or shipment of the sample by non-certified personnel

102
Q

During a study under an IND the investigator places the data on a laptop and the laptop is stolen. The date it was not encrypted. The event is

A

A protocol deviation and unanticipated event of risk to self or others

103
Q

A protocol deviation should be

A

Reported to the IRB on forms designated for such reports

104
Q

The protocol deviation should be reported to the IRB

A

Promptly and within the prescribed institutional guidelines

105
Q

Protocol deviations are reportable to the FDA

A

If the event is associated with a serious adverse event

106
Q

An independent DSMB for a clinical trial reaches a decision communicated in its report that the clinical trial be stopped for safety. The DSMB report should be sent to

A

The sponsor

107
Q

DSMB’s primary responsibility is to review

A

Safety and efficacy as defined intervals

108
Q

a decision to stop a phase 2 or phase 3 trial at all sites is the responsibility of

A

DSMB

109
Q

The sponsor in a phase 2 clinical trial may

A

Choose to delegate a valuations of safety at the site to the principal investigator

110
Q

The frequency of meetings of the DSMB may be

A

Based on a specified frequency in time, based on the number of serious adverse events observed, or based on the number of patients in rolled

111
Q

A major problem in the DSMB for a sponsor-investigator clinical trial is

A

Conflict of interest with the principal investigator

112
Q

If the DSMB suspends a clinical trial the IRB

A

My suspend the clinical trial added the site

113
Q

The Nuremberg code was formulated by

A

The Nazi war crimes tribunal

114
Q

Which of the following items is part of the Nuremberg code

A

Voluntary consent of the human subject is absolutely essential, the experiment should yield fruitful results for the good of society, the experiment should be based on animal experimentation and a knowledge of the natural history of disease, and no experiment should be conducted if there is a reason to believe that death or disability injury will occur

115
Q

With regard to stopping rules for clinical trials in the Nuremberg code which of the following applies

A

The human subject should be at liberty to bring an experiment to an end if he has reached a physical or mental state were continuation seem to be impossible, the scientist in charge must be prepared to terminate the experiment if he has cost to believe that continuation as likely to result in injury disability or death, and the number code foreshadows the subsequent use of data and safely monitoring boards and the subsequent mandatory use of stopping rules and clinical trials.

116
Q

The principle of justice in the Belmont report relates to

A

Distribution of burdens and benefits

117
Q

Respect for persons in the Belmont report refers to

A

Decision on the part of subjects to voluntarily participate or not in the research

118
Q

Which of the following is cited as an influence in the Belmont report

A

Nuremberg war crimes trial involving Nazi medical experiments

119
Q

The three principles in the Belmont report relate to

A

Respect for persons, beneficence , and justice

120
Q

The IRB should refer to the principle of beneficence in the Belmont report when it is evaluating

A

Risk to benefit ratio

121
Q

The Belmont report addresses

A

Differences between practice and research

122
Q

The Belmont report was formulated by

A

The national commission for the protection of human subjects in biomedical and behavioral research

123
Q

The commission that formulated the Belmont report was created as part of

A

The national research act of 1974

124
Q

The declaration of Helsinki was formulated by the

A

World medical Association

125
Q

Which of the following ethical framework has been revised on several occasions

A

The declaration of Helsinki

126
Q

Regarding the use of placebos in clinical trials the declaration of Helsinki states that

A

The benefit rests and burdens of a new intervention must be tested against the best proven intervention, placebo maybe used when for sans methodical reasons is important to determine safety and efficacy of the intervention, and the use of placebo will not result in additional risk or serious or irreversible harm to the subject relative to not receiving the best possible intervention

127
Q

Researched is defined as

A

Systematic investigation to develop or contribute to generalizable knowledge

128
Q

Intervention for research purposes involves

A

Physical procedures by which data is gathered such as vein puncture or any manipulation of the subject or the subjects environment

129
Q

In order to assess protected health information of a child, HIPAA requires

A

Parental authorization from one parent

130
Q

The best method for protection of confidentiality of electronic data is

A

Password protection and encryption of the data

131
Q

An IRB requires a witness for the consent form. It also requires a HIPAA authorization. The witness should

A

There is no witness provision for the HIPAA form

132
Q

And investigator wishes to review medical records for the purpose of determining the number of eligible subjects. He will probably qualify for

A

A partial waiver of HIPAA preparatory to research

133
Q

The HIPPA authorization requires

A

The signature and date of the individual

134
Q

Limited data sets can only use the following identifiers

A

A date and ZIP Code

135
Q

In a study that involves children, the investigator must obtain for access to protected health information

A

A HIPPA Authorization from the parent only

136
Q

A study monitor requests access to the entire medical record of the subject as a means of assessing source documents for the data collected. The most likely course of action is

A

Under the minimum necessary rule this access may be denied as the medical record contains private information unrelated to the clinical trial

137
Q

Payments to research subjects should be based on

A

Time and inconvenience

138
Q

According to FDA guidance the payments to research subject should be

A

Should be prorated in accordance with the research related visits

139
Q

In assessing the payments to subjects in light of the Belmont report the IRB should be concerned about

A

The principle of justice

140
Q

According to the FDA guidance on recruitment for studies under an IND, the following information needs to be reviewed by the IRB

A

Protocol, consent forms, recruiting scripts, investigators brochure

141
Q

A physician wishes to inform his patients about a clinical trial for which he is the principal investigator, he should

A

Leave the clinical trial brochures in his waiting room and provide his research staff member as the contact for further information

142
Q

The certificate of confidentiality is meant to protect

A

Research subjects

143
Q

The certificate of confidentiality is designed

A

To prevent compelled disclosure of research subject information in the event of a court order to release such information

144
Q

Withdrawal of subjects from research study implies that

A

Activities involving interaction or intervention will stop, assessing identifiable private information about the subject be discontinued, and observation or recording of private behavior must be stopped

145
Q

If an investigator terminate the subjects participation in a clinical trial, according to OHRP guidance the investigator should

A

Assess subject of participation in secondary interventional component should continue

146
Q

According to the FDA, if the subject withdraws from a clinical trial

A

All data collected up to the time of withdrawal must remain in the trial database in order for the study to be scientifically valid

147
Q

According to HIPAA if the research subject revokes a HIPAA authorization

A

The revocation has to be in writing, we revocation does not affect use or disclose of data prior to the revocation

148
Q

An IRB is converting its paper records to an electronic system. An important consideration would be

A

Part 11 compliance of the new system

149
Q

And electronic informed consent

A

May take place on site or remotely, must have a method to ensure the identity of the subject participating in the study, and must have processes in place in order to answer the subjects questions

150
Q

An electronic signature is one which is

A

Symbols which are legally binding equivalent of a hand written signature, unique nonassignable certifiable, may not be copied or excised.

151
Q

Ensuring the identity of the subject and electronic informed consent may employ

A

Verification of a state issued identification, use of personal questions, and or biometric or visual methods.

152
Q

A 1572 is a contract between

A

Investigator and FDA

153
Q

All the following are required on a form 1572

A

The principal investigator CV, information on other investigators, laboratory facilities utilized, IRB information.

154
Q

The investigators brochure is a central part of the submission of an IND

A

Form 1571

155
Q

Form 1571 includes

A

The protocol, the investigators brochure, the chemistry manufacturing and control section, and pharmacology and toxicology data.

156
Q

The sponsor may charge a subject for an investigational drug if

A

With written permission from the FDA

157
Q

A sponsor who makes a cardiac pacemaker has secured a IND for the device. The sponsor decides to make a mirror modification to the pacemaker. The sponsor must

A

File an IDE because it is significant risk device

158
Q

An IND is required before a new device

A

Can be evaluated in a clinical trial and shipped across the state lines.

159
Q

A HUD is a device

A

Applicable to less than 4000 individuals, a device for which a clinical trial to prove effectiveness is not required, for which no comparable device exists on the market

160
Q

A significant risk device is

A

Implantable, poses a serious risk to health, mitigate serious risk to subject, essential for diagnosis, treatment or cure

161
Q

Before a HUD is used in a hospital the application must

A

Have a review and approval from the IRB

162
Q

An investigator participating in a device study must complete

A

And investigator agreement

163
Q

Financial disclosure and clinical trial under an IND is done on

A

Form 1571

164
Q

With respect to financial disclosure by the principal investigator in a clinical trial be FDA requires

A

Disclosure of any financial arrangement, financial arrangements that could influence the outcome of the study, and financial arrangements that meet the threshold requirements set forth in form 3455.

165
Q

FDA requires the disclosure by the principal investigator and financial payments of an amount greater than

A

$25,000

166
Q

FDA requires disclosure by the principal investigator of equity interest greater than

A

$50,000

167
Q

FDA requires disclosure by the principal investigator of proprietary interest including

A

Patons, copyright or trademark, intellectual property

168
Q

FDA requires reporting of any financial interest of the principal investigator in the sponsor

A

Immediately before the trial begins, during the clinical trial, for a period of one year after the study closure at the site

169
Q

The principal investigator in an IND study owns shares in a mutual fund that invest in the stock of the sponsor as one of its holdings. The investigator

A

Need not disclose this to the FDA on form 3455

170
Q

The principal investigators wife owns equity interest greater than $50,000 directly in the sponsors stock. The principal investigator must

A

Disclose this to the FDA on form 3455

171
Q

The principal investigator received a cash payment for consultation from the sponsor in the amount of $10,000. This amount is

A

Below the threshold amount for disclosure to the FDA, may have to be disclosed to the conflict of interest committee, and may have to be to disclose to the IRB if required by the institutional guidelines.

172
Q

The conflict of interest committee reviewing the disclosure of a PI on an FDA clinical trial in the amount of $10,000

A

May require the PR to transfer consenting responsibilities to others on the research team, may require the PR to transfer the principal investigator duties to the coinvestigator who does not have a conflict of interest, may develop a customized conflict of interest management plan specific to the situation

173
Q

The threshold payment amounts to be disclosed to the institutional conflict of interest committees in most institutions

A

Are less than the FDA guidelines

174
Q

The study is designed to first introduce a drug in human beings are

A

Phase 1

175
Q

The studies with the highest risk to benefit ratio are

A

Phase 1

176
Q

The studies with lowest number of subjects as likely to be

A

Phase 1

177
Q

The study is most likely to use healthy volunteers are likely to be

A

Phase 1

178
Q

The study is most likely to employ the use of drug registry are likely to be

A

Phase 4

179
Q

The study is most likely to influence the labeling of the drug and its approval by the FDA are

A

Phase 3

180
Q

The studies which do not require an IND are

A

Phase 4

181
Q

The studies which are likely to have the longest duration are

A

Phase 4

182
Q

The studies which are likely to provide the earliest reliable information about efficacy are

A

Phase 2

183
Q

A study enrolls 100 subjects is most likely to be

A

Phase 2

184
Q

A phase 1 study is likely to evaluate

A

Dose limiting toxicity, maximum tolerated dose, and half life.

185
Q

A drug that has a half life on one day and has an initial plasma concentration of 100 mg. The concentration after four days is

A

6.25

186
Q

A drug has a half-life of one day and a minimum affect concentration of 12.5 mg. It has an initial concentration of 100 mg. The drug will stop being affective after

A

Four days

187
Q

The minimum number of subjects that can be enrolled in a clinical trial is

A

One

188
Q

Phase 1 studies are likely to provide the least reliable data on efficacy because

A

Effects are unlikely at the lowest dose is tested.

189
Q

In a phase 1 oncology study and adults the subjects are likely to be

A

Patients with cancer who have failed standard therapy.

190
Q

In a phase 3 trial subjects are randomize to treatment group and a control group the assignments remain unchanged for the duration of the trial this is an example of what study design

A

Parallel design

191
Q

The declaration of Helsinki advises this design for clinical trials whenever possible

A

Treatment drug with a comparator

control

192
Q

Bias in clinical trial can result from

A

Aspects of trial design, operational aspects of the trial, statistical analysis and evaluation of the results.

193
Q

The most common techniques utilized to prevent bias in a clinical trial R

A

Randomization in blinding

194
Q

In a two group parallel design trial neither the investigator nor the subject is aware of whether the group is the treatment drug or a placebo. This is an example of

A

Double blinding

195
Q

In a double blind placebo controlled design the reasons for the blinding of the investigator include

A

Prevent the investigator from reviewing the treatment group more strenuously, prevent the investigator from not recording or reporting serious adverse events in the treatment group, prevent the investigator from making protocol changes which favor of the treatment group.

196
Q

The goals of a phase 4 trial include

A

Detection of rare side effects, detection of side effects associated with chronic use of the drug, and desensitization and loss of the fact of the drug upon continued treatment.

197
Q

And important rare side effect is observed for a drug phase for trial. The likely outcome would be

A

The sponsor reports it to the FDA which then imposes a black box warning on the product label.

198
Q

Drug trial, which phase would most influence FDA approval and the final product label for a drug is

A

Phase 3

SOCRA SAMPLE QUESTIONS (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions